Biothrax Global Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

Biothrax is a vaccine developed to protect against anthrax, a serious and potentially life-threatening disease caused by the bacterium Bacillus anthracis. The vaccine functions by stimulating the immune system to generate antibodies against anthrax toxins, which can be fatal if exposure occurs, particularly in bioterrorism-related situations.

The main types in the Biothrax market include live vaccines and cell-free protective antigen vaccines. Live vaccines are produced from weakened, or attenuated, organisms that do not cause disease but effectively trigger a strong immune response. The clinical indications include pre-exposure prophylaxis and post-exposure prophylaxis. The vaccine is used for both human and animal applications, and the end users include hospitals, clinics, vaccination centers, and other healthcare facilities.

Tariffs have influenced the biothrax market by increasing costs associated with imported vaccine ingredients, sterile vials, and cold-chain logistics equipment. These impacts have affected government procurement budgets, particularly in regions that rely on cross-border sourcing for biodefense vaccines. Hospital and vaccination center segments in regions such as asia-pacific and middle east are more sensitive to tariff-driven cost fluctuations. At the same time, tariffs have encouraged domestic vaccine manufacturing, strengthened national stockpiling capabilities, and improved long-term biodefense supply security.

The biothrax market research report is one of a series of new reports from The Business Research Company that provides biothrax market statistics, including biothrax industry global market size, regional shares, competitors with a biothrax market share, detailed biothrax market segments, market trends and opportunities, and any further data you may need to thrive in the biothrax industry. This biothrax market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The biothrax market size has grown strongly in recent years. It will grow from $0.93 million in 2025 to $1.01 million in 2026 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to bioterrorism threat awareness, government-funded vaccine programs, military immunization requirements, historical anthrax exposure incidents, reliance on centralized vaccination campaigns.

The biothrax market size is expected to see strong growth in the next few years. It will grow to $1.4 million in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to increased homeland security investments, rising global biodefense collaborations, expansion of emergency preparedness policies, growth in animal anthrax prevention programs, modernization of vaccine storage infrastructure. Major trends in the forecast period include rising focus on biodefense preparedness, expansion of government stockpiling programs, increased use of pre-exposure prophylaxis vaccination, growing emphasis on emergency response readiness, strengthening of national immunization security programs.

The increasing consumption of meat is expected to drive the growth of the BioThrax market going forward. Meat consumption is influenced by factors such as rapid urbanization, rising income levels, changing dietary habits, and cultural preferences that emphasize meat as a major source of protein and nutrition. BioThrax is used to vaccinate livestock against anthrax, a disease that can be transmitted through contaminated meat, thereby helping ensure meat safety and protecting public health from zoonotic disease outbreaks. For instance, in June 2023, according to the Food and Agriculture Organization of the United Nations, global meat production increased to 363.9 million metric tons in 2023. Thus, the rising consumption of meat is contributing to the growth of the BioThrax market.

The growing prevalence of anthrax is also expected to propel the growth of the BioThrax market going forward. Anthrax prevalence is largely driven by the persistence of Bacillus anthracis spores in soil, which can infect animals and humans through contact or ingestion. BioThrax is a vaccine that helps prevent anthrax by stimulating the immune system to produce antibodies against Bacillus anthracis, thereby reducing the risk of infection. For instance, in December 2023, according to the World Health Organization, Zambia reported 684 suspected human anthrax cases as of November 2023, including four deaths, corresponding to a case fatality ratio of 0.6%. Thus, the increasing prevalence of anthrax is driving the growth of the BioThrax market.

Major companies operating in the BioThrax market are concentrating on strategic investments to strengthen production capacity, expand their geographic reach, and develop advanced anthrax vaccines. Strategic funding supports clinical trials and helps meet regulatory requirements, enabling companies to secure approvals across multiple countries. This, in turn, improves the availability of vaccines in underserved regions. For instance, in January 2024, Emergent BioSolutions, a US-based biotechnology company, received a major contract valued at up to $235.8 million from the U.S. Department of Defense (DoD) to supply BioThrax (Anthrax Vaccine Adsorbed) for military use. This contract highlights the continued demand for effective anthrax vaccines within the U.S. military and demonstrates Emergent's long-standing partnership with government agencies in delivering biodefense solutions.

Major companies operating in the biothrax market are Emergent Bio-Solutions

North America was the largest region in the biothrax market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biothrax market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the biothrax market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

The biothrax market consists of sales of single-dose vials and multi-dose vials. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Biothrax Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses biothrax market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for biothrax ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The biothrax market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Live Vaccines; Cell Free Protective Antigen Vaccines
• 2) By Clinical Indication: Pre-Exposure Prophylaxis; Post-Exposure Prophylaxis
• 3) By Application: Human Use; Animal Use
• 4) By End-User: Hospital; Clinics; Vaccination Centers; Other End-Users
• Companies Mentioned: Emergent Bio-Solutions
• Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.